SciClone Shareholder Settlement Suggests New Trend in FCPA Derivative Suits

SciClone Pharmaceuticals Inc.’s Dec. 15 settlement with shareholders in a Foreign Corrupt Practices Act derivative suit may mark a new focus on corporate governance initiatives as plaintiff lawyers seek quick-hit legal fees.

Unlock unlimited access to all Global Investigations Review content